DD
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HUGE BUYING OPPORTUNITY. THIS STOCK WON'T SEE THIS PPS AGAIN.
LOADING. PPS WON'T LAST LONG
Good, realistic article. Its been a bumpy ride. But my confidence in these guys and their drug line is so high, I'm just buckling my seatbelt and keeping my eyes on the prize. Propanc will revolutionize the treatment of cancer, I have no doubt about it These guys are intelligent, experience and have stumbled upon something so novel, that it would be a huge surprise were it not to make it to market. The PR on successful animal studies will be huge and we are expecting it in the next week or so. Plus preliminary animal testing and human testing have shown the safety and efficacy of PRP. On top of it all, they have a drug pipeline that looks very promising. I'm not gonna miss out on this one because its gonna be big$$$$$$$$$$$
Propanc is Becoming a Global Company (Australia England, Spain, Grenada). When their PRP and POP1 are released (and they already have drug patents in US, Europe and South Africa) the demand is going to incredible$$$
GONNA BE SOME SERIOUS INTEREST IN DMHI IN THE COMING WEEKS>
BIG RUN COMING. BIG NEWS COMING TOO....
With Animal Studies Success and ODD Status Granted by FDA, We will All be $$$
3 Academic Research Partnerships: PRP and now POP1 on Track for FDA Approval. Hold and Buy.
PRP and now POP1 with it's own official research program at the University of Jaen, Spain This is gonna be big $$$
PRP IS MULTI FUNCTIONAL: STAND ALONE TREATMENT, ADJUNCT TO CHEMO AND OR SURGERY AND PREVENTATIVE TREATMENT FOR THOSE AT HIGH RISK FOR DEVELOPING CANCER. PRP IS THE TRIFECTA!!! MULTIPLE INDICATIONS MEANS HIGH VALUE
England is going to be making some moves...Gonna be BIG for DMHI. FINALLY!
PPCH is relentless; PRP will go to market and be a huge success
An international consortium- U. Bath, U. Grenada, U. Jaen. Time to see silver
PPCH's TIME IS CLOSE AT HAND. IT'LL BLAST OFF IN THE BLINK OF AN EYE
PRP IS MULTI FUNCTIONAL: STAND ALONE TREATMENT, ADJUNCT TO CHEMO AND OR SURGERY AND PREVENTATIVE TREATMENT FOR THOSE AT HIGH RISK FOR DEVELOPING CANCER. PRP IS THE TRIFECTA!!! MULTIPLE INDICATIONS MEANS HIGH VALUE
Propanc + 3 Huge Academic Research Partners = Efficiency and Products Fast Tracked
BIG RESULTS JUST AROUDN THE CORNER. FDA IND APPROVAL IS CLOSE AT HAND!
Propanc multiple cancer drugs actively coming down the pipeline. Propanc is barreling ahead and is grabbing interest from some of the world's top cancer researchers and university oncology programs
Propanc Announces Joint Research Partnership with University of Jaen, Spain
Posted: Mar 19, 2015 10:02 AM PDT
Updated: Mar 19, 2015 11:34 PM PDT
This article was originally distributed via SproutNews. SproutNews, WorldNow and this Site make no warranties or representations in connection therewith.
MELBOURNE, AUSTRALIA / ACCESSWIRE / March 19, 2015 / Propanc Health Group Corporation (PINKSHEETS:PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on the development of new and proprietary treatments for cancer patients, today announced it has commenced the second stage of its POP1 research program with the University of Jaen, Spain, to investigate further the anti-cancer effects and cellular mechanisms associated with proenzymes as a treatment for cancer. The aim is to identify new patentable drugs as back up compounds to the Company’s lead product, PRP.
“Jaen, Granada and Bath Universities were all significant contributors to our initial research, when we previously undertook laboratory studies to elucidate how PRP works and to identify patentable opportunities. Not only did we end up jointly filing a patent with Bath University around the world, which we were assigned the commercial rights to, but were able to publish key scientific discoveries in a peer reviewed journal. Our lead experimentalist, Dr Macarena Peran, did an excellent job in bringing these Research Institutions together and I look forward to collaborating with her over the course of this year and beyond,” said James Nathanielsz, Propanc’s Chief Executive Officer. “Our intention is to aggressively screen and develop new compounds for future development as a back up to our lead product, PRP. We hope to establish an exciting new treatment class in oncology which complements existing treatments and helps reduce the threat of tumor recurrence and metastasis. This is part of our strategic plan.”
About Propanc:
We are a development stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancer. Together with our scientific and oncology consultants, we have developed a rational, composite formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our leading products are variations upon our novel formulation and involve or employ proenzymes, which are inactive precursors of enzymes. As a result of positive early indications of the anti-cancer effects of our technology, we intend to submit our proenzyme treatment to the rigorous, formal non-clinical and clinical development and trial processes required to obtain the regulatory approval necessary to commercialize it and any product(s) derived and/or to be derived therefrom.
In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors such as colorectal or pancreatic tumors. In the future, we intend to development our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, please visit: www.propanc.com.
Forward-looking Statements:
Certain of the matters discussed in this announcement involve risks and uncertainties including, without limitation, those regarding the Company’s ability to establish and maintain the proprietary nature of its technology through the patent process, its ability to license from others patents and patent applications, if necessary, to develop certain products, its ability to implement its long range business plan for various applications of its technology, and its ability to enter into agreements with any necessary marketing and/or distribution partners for purposes of commercialization. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company’s financial position. See Propanc’s most recent Quarterly Report on Form 10-Q and related 8K filings.
Contact:
Regal Consulting
Tel: 702 – 575 – 9157
SOURCE: Propanc Health Group Corporation
ReleaseID: 427011
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com
PRP and now POP1 with it's own official research program at the University of Jaen, Spain This is gonna be big $$$
This is going beyond Propanc...its an international consortium
Propanc is gonna be bigger than we originally imagined. According to CEO Nathanielz, "We hope to establish an exciting new treatment class in oncology which complements existing treatments and helps reduce the threat of tumor recurrence and metastasis."
When PRP gets Orphan Drug Status, this is gonna go boom.
And it will happen in the blink of an eye. BUY HOLD AND WAIT FOR YOUR PROFITS
Do your DD my friend. I'll share some here:
Actually, EvaluatePharma® finds that 16 new orphan drugs (NMEs/ BLAs and biologicals) were approved in 2013 out of 35 new drugs. Orphan drugs represented 46% of the industry's new drug output in 2013. Overall the FDA approved 32 designations in 2013 vs. 2012. This includes new indication approvals of already marketed products.
Worldwide Orphan Drug Sales Forecast to Total $176bn (CAGR 2014 to 2020: +10.5%); Double Overall Rx Market Growth. Orphan Drugs Set to be 19.1% of Worldwide Prescription Sales by 2020 (excluding generics)
EvaluatePharma® finds that the market for orphan drugs, based on the consensus forecast for the leading 500 pharmaceutical and biotechnology companies, will grow by 10.5% per year (CAGR) between 2014 and 2020 to $176bn.
The growth of the orphan drug market is almost double that of the
overall prescription drug market, which is set to grow by 5.3% over the period 2014-2020.
Orphan drugs are set to account for 19.1% of global prescription sales in 2020, excluding generics, up from 6.3% in 2000.
In 2013 orphan drug sales increased 6.8% to $90bn vs. 2012, in contrast to non-orphan drug sales which decreased by 0.9% to $560bn.
http://opinionator.blogs.nytimes.com/2013/06/30/the-orphan-jackpot/?_r=0
http://info.evaluategroup.com/rs/evaluatepharmaltd/images/2014OD.pdf
ODD announcements result in pps blast offs. Try doing a google image search of ODD stock chart announcements. It's amazing.
Propanc May Get Orphan Drug Designation = Fast Track to Human Trials
First off, according to Professor Klaus Kutz, “Once we have assessed and identified the most effective dose in animals, we plan to meet with the FDA (Food and Drug Administration), to discuss and agree upon the planned formal preclinical program to support an Investigational New Drug Application (IND) to commence human trials in 2015," said Professor Klaus Kutz, Chief Medical Officer at Propanc Health Group. "Depending on the final indication selected for our initial patient trials, we may also seek Orphan Drug Designation for our treatment given the novelty of our proenzyme formulation and depending on the size of the target patient population we propose for trials."
So what’s the big deal about ODD?
“The industry has rushed to develop orphan drugs in recent years because they cost their developers less to put through clinical trials, and command higher prices when they do launch. Trial sizes are naturally smaller than for diseases with large populations, and the lack of alternative treatments give orphan agents an advantage when up for regulatory review. Tax incentives reduce development costs further. And when orphan drugs do reach the market, on average their cost per patient is six times that of non-orphan drugs, a clear indication of their pricing power.”
Or as Stephen Rattner of NY Times put it, referring to the monstrous climb in the PPS of Jazz Pharmaceuticals, “to get drug developers to focus on these relatively small pools of patients, the federal government offers inducements like a 50 percent research-and-development tax credit as well as a longer period of market exclusivity (seven years after Food and Drug Administration approval, rather than the typical five). These long monopolies often give orphan drug makers a free hand to raise prices.”
http://opinionator.blogs.nytimes.com/2013/06/30/the-orphan-jackpot/
Other facts about ODD:
1. Worldwide orphan drug sales forecast to total 176 billion, almost double overall prescription market growth (excluding generics).
2. Orphan drugs set to be 19.1% of worldwide prescription sales by 2020 (excluding generics)
3. Median cost per patient differential 19 times higher for orphan drugs compared to non-orphan
4. Bristol-Myers Squibb set to climb to number one position in orphan drug sales to 2020
5. Phase III orphan drug development cost half that of non-orphan; potentially a quarter with US tax breaks
6. Phase III drug development time for orphan is no quicker than non-orphan
7. Orphan drug FDA approval time 10 months vs. 13 months for non-orphan
8. Expected return on investment of phase III/ filed orphan drugs 1.89 times greater than non-orphan drugs
See the link below for full Evaluation Report of 2014 Orphan Drugs:
insert-text-here
P.S. Image searching stock charts when ODD is announced show immediate blast-offs. Check it out.
Propanc's Professor Klaus Kutz, M.D., CMO
He will bring PRP through successful human trials, IMO.
Professor Kutz has ten years of experience as independent consultant in Clinical Pharmacology and Safety for pharmaceutical companies and clinical research organizations. His specialty over the last six years is Oncology, including preparation of multiple NDAs and INDs for small and medium sized pharmaceutical companies. He has prepared, organized and reported clinical Phase I studies in oncology and Phase II studies in different cancer indications (prostate, gastric, ovarian, small cell lung cancer) and Non-Hodgkin Lymphomas.
Professor Kutz has more than 12 years experience as Head of Clinical Pharmacology with world-wide responsibilities for Phase I and Clinical Pharmacokinetics in two internationally operating pharmaceutical companies, setting up and restructuring international Clinical Pharmacology departments. His achievements include the successful world-wide registration of multiple important Sandoz’ compounds by preparation of multiple NDAs (New Drug Applications) and Expert reports (including Written Summary), as well as the preparation of multiple INDs (Investigational New Drug Applications) for Sandoz Pharma Ltd and Sanofi Research. A specialist for Internal Medicine, Gastroenterology, and Clinical Pharmacology, he is also Professor of Medicine at the University of Bonn, Germany.
Huge Plus**: Propanc's John Smythe serves on the **Expert Oncology Advisory Group to the European Drug Licensing Board**. If he had any doubt that PRP would not get FDA approved, I don't think he would be the leader on Propanc's scientific advisory board.
INTERVIEW HIGHLIGHTS
Interview Highlights:
-- Learn how DMHI continues to develop and utilize their Virtual Physicians
Network healthcare mobile platform
-- How can technology reduce unwarranted treatment variations and reduce
exorbitant healthcare cost
-- Collecting and analyzing clinical outcomes on all surgical patients and
not just those enrolled in studies. DMHI effectively collects and
analyzes feedback from all the stakeholders' in the surgical process
-- Continue to keep patient privacy a focus as technology continues to push
the reliability of everyone's privacy
Listen to George England's Interview$$$
http://www.iheart.com/live/talk-radio-640-wgst-6066/?autoplay=true&pname=15153&campid=play_bar&cid=main.html.
HUGE NEWS! DMHI GEORGE ENGLAND INTERVIEWED ON RADIO!
Heart Radio/ Clear Channel Atlanta Studios - 640 WGST AM Featured Doctors Mobile Healthcare International on "HealthTech Talk Live"
6 hours 48 minutes ago - DJNF
iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM Featured Doctors Mobile Healthcare International on "HealthTech Talk Live"
Interview Archive Now Available -- March 16, 2015
CORAL SPRINGS, FL--(Marketwired - Mar 17, 2015) - "HealthTech Talk Live, " hosted by Ben Chodor and broadcasted every Saturday from 3-4pm ET on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM, is proud to announce that the interview archive of Doctors Mobile Healthcare International's CEO George England is now available. Doctors Mobile Healthcare International (OTCBB: DMHI) is a company dedicated to help surgeons, medical institutions and medical vendors improve clinical and financial outcomes by utilizing their intuitive mobile healthcare platform that focuses on these core values: increasing accountability, improving clinical outcomes, driving revenue, and saving time and money. In this captivating double-segment interview, Mr. England discussed why it's critically important to keep everyone accountable among all the stakeholders that deliver care to patients especially around the surgical space.
US. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen to the link below:
NOW AVAILABLE: PLAY INTERVIEW ARCHIVE
Show Details:
Network: iHeart Radio/ Clear Channel
Station: 640 WGST AM
Show: HealthTech Talk Live
Host: Ben Chodor
Interview Highlights:
-- Learn how DMHI continues to develop and utilize their Virtual Physicians
Network healthcare mobile platform
-- How can technology reduce unwarranted treatment variations and reduce
exorbitant healthcare cost
-- Collecting and analyzing clinical outcomes on all surgical patients and
not just those enrolled in studies. DMHI effectively collects and
analyzes feedback from all the stakeholders' in the surgical process
-- Continue to keep patient privacy a focus as technology continues to push
the reliability of everyone's privacy
About Doctors Mobile Healthcare International
Doctors Mobile Healthcare International is a public company dedicated to help surgeons, medical institutions and medical vendors improve clinical and financial outcomes by utilizing our intuitive mobile healthcare platform that focuses on these core values: Increasing Accountability, Improving Clinical Outcomes, Driving Revenue, and Saving Time and Money.
About CEO George England
Mr. England is currently the CEO of DHMI with over 26 years of experience as a healthcare entrepreneur and executive. His professional background is firmly rooted in the healthcare industry with over 26 years of consulting, building businesses and working with national healthcare companies such as Synthes, Osteotech, K2M and Nuvasive. Mr. England has also consulted with several national start-up companies in the healthcare vertical with a focus on fundraising and corporate development.
About iHeart Radio/ Clear Channel
Clear Channel's Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more Information Visit: http://www.iheart.com/live/talk-radio-640-wgst-6066/?autoplay=true&pname=15153&campid=play_bar&cid=main.html.
About HealthTech Talk Live
HealthTech Talk Live broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm - 4:00pm EST every Saturday. Host Ben Chodor interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from making people healthier. It's a fast moving, high-energy show... shift your thinking and join us as we deliver "tomorrow's ideas today" on iHeart Radio and Clear Channel's HealthTech Talk Live. Visit iHeart Radio's HealthTech Talk Radio Show or visit www.HealthTechTalk.com.
Propanc Raises Capital to Complete Next Round of Animal Studies
http://finance.yahoo.com/news/propanc-raises-capital-complete-next-130000778.html
FINANCING FOR ANIMAL STUDIES FROM INSTITUTIONAL INVESTORS IS HUGE. NEXT PR WILL BE APPROVAL FROM FDA TO MAKE PRP INVESTIGATIONAL NEW DRUG, HOPEFULLY ORPHAN DRUG WHICH WOULD FAST TRACK HUMAN TRIALS.
Dr. Ralph Brandt of Propanc: Successfully led the tumor biology program for animal studies at Novartis. Novartis is now trading at $98 PPS!!!
Huge Plus**: Propanc's John Smythe serves on the **Expert Oncology Advisory Group to the European Drug Licensing Board**. If he had any doubt that PRP would not get FDA approved, I don't think he would be the leader on Propanc's scientific advisory board.
FYI: Klaus Kutz, CMO of Propanc has prepared multiple investigational new drugs (IND) FDA applications for Sanofi. And Sanofi is now trading at just around $48 per share. Just in case you needed some reassurance that Propanc is in good hands heading into meetings with FDA and eventually, human trials.
Good time to buy in, doors are closing. Funny, I posted "a good time to buy in" a couple days ago when it was at .013.
Great indeed! Once that PR hits re: successful animal studies or FDA IND approval, we'll take off. I'm really hoping they get Orphan Drug Status...that could really speed things along and would cost them significantly less to run the human trials. And ODD drugs have on average a higher pps once they hit human trials and the market. I'm hopeful we have the next Jazz Pharma here.
On another note, I talked to a couple of oncologists at a well known academic hospital (I come from a family of doctors though I went the research route) and they were quite familiar proenzyme therapy, noting they have been waiting for someone to put in the time and resources to get this type of drug approved. Apparently it can function as a preventative treatment for those at high risk for developing cancer, a first line treatment for those with early stage cancer, and a maintenance drug to control spread and extend life for those in late stage. It also has numerous routes of administration. For example, it can be directly injected into tumors to stop metastatic growth. Or it can be used as an adjunct to surgical removal of tumors to prevent re-occurrence/metastatic growth following surgery to sustain cancer remission.
With so many uses, I think PRP (and its various forms) are gonna be revolutionary for the medical community in terms of treating cancer. Plus, although they are focusing on colorectal and pancreatic cancer, proenzyme therapy is by no means contraindicated for use in the treatment of all kinds of metastatic disease. Just depends on what FDA approves it for. But drugs can always be used for off label purposes.
Loving this slow climb up. It's so stealth. Then suddenly, it will take off. DON'T MISS IT.